DEVICE INNOVATION AWARD

2026 Award

Additional Ventures, in partnership with the Consortium for Technology & Innovation in Pediatrics (CTIP), is pleased to announce a funding opportunity to support the advancement of medical device innovation, designed to accelerate the development of novel medical devices that address critical needs in single ventricle heart disease, to improve outcomes and address core physiological challenges or high-burden sequelae.

This joint initiative brings together Additional Ventures’ commitment to transforming outcomes for patients with single ventricle heart disease and CTIP’s deep expertise in medical device development and commercialization. Together, the partners will provide both the financial support and technical resources needed to advance high-potential technologies from concept toward clinical and commercial impact.

Through this initiative, innovators can receive up to $1M in milestone-driven funding, for up to approximately 3 years in total, with the access to advising, services, and support throughout the award term. Funds may be used for key activities essential to moving medical devices from concept to clinical impact. Awardees will also benefit from CTIP’s tailored support services, including coaching, expert connections, and access to consulting and service providers.

Submissions Closed

Award Process & Timeline

Letters of Intent

We anticipate selecting up to 5 projects for funding in 2026. Decision making will be informed by peer review at multiple evaluation steps; however, program leadership reserves the right to make ultimate funding decisions on any application. If multiple applications are submitted by the same project lead, only one may be selected for funding.

LOIs will be evaluated by a joint Additional Ventures-CTIP review committee and may be evaluated by experts outside the area of an applicant’s focus area. Written critiques will not be provided to applicants who are not invited to the full application stage. 

Submissions Closed

The Basics

  • Open to U.S.-based academic institutions and companies developing medical devices aimed at improving outcomes in single ventricle heart disease

  • Up to $1M in milestone-driven funding

  • 3 year grant term

Eligibility Criteria

✓ Must be a novel pediatric medical device or technology.

✓ Medical devices must meet the FDA definition of a medical device. At this time, Software as a Medical Device is not eligible.

✓‍ ‍Development of novel drugs and chemical therapies will not be funded. Process improvement and innovations are also not eligible for
funding.

✓‍ ‍Projects must be a pediatric medical device or technology innovation that leads to improved patient experience, quality, outcomes, or
efficiency.

✓‍ ‍Eligible projects must have clear achievable milestones for the funding period with specific metrics or deliverables.

✓‍ ‍Indirect rates are limited to 10% of the overall budget. See Additional Ventures’ indirect cost policy.

FAQs

Applying

  • Applications are encouraged from both companies and academic institutions. Funding decisions are based on the merit of the project and feasibility of the milestones with respect to funding.

  • Yes. While CTIP’s core mission includes pediatric innovation, this program is not limited to pediatrics. Devices that address needs across the lifespan of single ventricle patients (from childhood through adulthood) are eligible.

  • At the leadership level, teams must include a coordinating project lead and appropriate clinical and technical expertise to support the success of their asset. Additionally, teams must include a project manager or equivalent operational lead responsible for day-to-day execution, coordination, and milestone tracking.

Use of Funds

  • Indirect costs will be calculated as a percentage of the overall award budget, up to 10%. See Additional Ventures’ indirect cost policy.

  • Projects may receive up to $1 million in total support over a 3 year period. It is anticipated that up to 5 projects will be selected for funding in 2026.

  • In-utero or fetal technologies are not elligible for the program at this time.

  • Funds may be used to support activities such as:

    • Concept and design selection

    • Prototyping and benchtop testing

    • Preclinical (e.g., animal) studies

    • Design freeze and optimization

    • Manufacturing process development

    • Regulatory pathway development

Other

    • Hands-on guidance from CTIP’s dedicated staff

    • Access to CTIP’s network of clinicians, engineers, regulators, and industry leaders

    • Connection to Additional Ventures’ clinical and scientific networks

    • Consulting services in regulatory, reimbursement, business development, and more

  • The deadline for the Letter of Intent Submission is November 6, 2025 at 11:59 pm PST. Applicants will be invited to submit a full proposal by mid December with the Full Proposal deadline of February 12, 2026, 5:00pm PST. Upon review, finalists will be invited to a virtual Finalist Presentation in May/June 2026 with the award announcement taking place in June 2026 and the funding beginning September 1, 2026.

  • No. All intellectual property belonging to the innovator or company will remain its own property irrespective of funding decision.